Dose escalation of RG6344 demonstrates safety and promising activity in BRAF V600E solid tumours
Dose escalation of RG6344 demonstrates safety and promising activity in BRAF V600E solid tumours
Phase I/II trial shows promising activity of invikafusp alfa in PD-1–resistant GI cancers
Nivolumab plus ipilimumab improves survival results in MSI-H/dMMR metastatic colorectal cancer
Key insights from head and neck research at ASCO 2025
Transforming cancer care in India: The Access Cancer Care Initiative
Lurbinectedin plus atezolizumab improves PFS and OS in ES-SCLC first-line maintenance
Encorafenib, cetuximab plus chemotherapy yields good response in BRAF V600E mCRC
Durvalumab and tremelimumab show manageable safety in poor-prognosis HCC
Independent clones in CLL show oligoclonality and early evolution patterns
Breast cancer survivorship
Burden and trends of breast cancer worldwide: Opportunities for prevention?
Odronextamab shows durable efficacy in R/R follicular lymphoma: 2-Year ELM-2 phase 2 results